News for Cocrystal Pharma, Inc. (COCP)

Cocrystal Pharma (COCP) revealed that its latest virology study demonstrates significant antiviral activity of its novel influenza PB2 inhibitor, CC-42344, agai

CC-42344 was shown to be highly active against the highly pathogenic 2024 Texas H5N1 avian influenza strain The Company's virology study further confirmed the p

Cocrystal Pharma (COCP) is making significant strides in developing a novel treatment for norovirus with its innovative oral pan-viral protease inhibitor, CDI-9

In vitro testing with CDI-988 demonstrated superior broad-spectrum antiviral activity against major norovirus variants BOTHELL, Wash., May 15, 2025 (GLOBE NE

Norovirus GII.17 variants have overtaken GII.4 as the most prevalent strain and significantly increased norovirus outbreaks in the U.S. and European countries i

BOTHELL, Wash., April 16, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. ( COCP) announces that Sam Lee, President and co-CEO, will present a Company overvie

NEW YORK, March 14, 2025 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced t...

**media[559086]**

Cocrystal Pharma, Inc. (COCP) Wednesday announced encouraging data from the Phase 1 study of its antiviral drug candidate CDI-988 for the treatment of Norovirus, Coronaviruses and Other viral infections.

U.S. stocks traded lower toward the end of trading, with the Dow Jones index falling more than 100 points on Tuesday. The Dow traded down 0.26% to 42,461.52 wh...

U.S. stocks traded slightly lower midway through trading, with the Nasdaq Composite falling around 50 points on Tuesday. The Dow traded down 0.05% to 42,554.24...

Cocrystal Pharma (COCP) stock plunged 40% Tuesday after the company said it plans to extend a Phase 2a challenge study for its influenza drug candidate CC-42344. Read more here.

U.S. stocks traded higher this morning, with the Dow Jones index gaining around 0.2% on Tuesday. Following the market opening Tuesday, the Dow traded up 0.19% ...

**media[503352]**

COCP stock touches 52-week high at $3.1 amid market optimism

The Company’s antiviral candidate for seasonal and pandemic influenza shows in vitro activity against the avian influenza A PB2 protein, whereas current...

BOTHELL, Wash., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces dosing of the first...

BOTHELL, Wash., Aug. 19, 2024 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc.’s (Nasdaq: COCP) management announces its participation in the upcoming Virtual...

BOTHELL, Wash., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces it has engaged hVIVO, a...